Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Receivables (2018 - 2025)

TransMedics (TMDX) has 8 years of Receivables data on record, last reported at $84.3 million in Q4 2025.

  • For Q4 2025, Receivables fell 13.75% year-over-year to $84.3 million; the TTM value through Dec 2025 reached $84.3 million, down 13.75%, while the annual FY2025 figure was $84.3 million, 13.75% down from the prior year.
  • Receivables reached $84.3 million in Q4 2025 per TMDX's latest filing, up from $80.7 million in the prior quarter.
  • Across five years, Receivables topped out at $142.0 million in Q1 2025 and bottomed at $4.1 million in Q3 2021.
  • Average Receivables over 5 years is $53.7 million, with a median of $54.1 million recorded in 2023.
  • Peak YoY movement for Receivables: plummeted 32.42% in 2021, then soared 430.96% in 2022.
  • A 5-year view of Receivables shows it stood at $5.9 million in 2021, then skyrocketed by 365.3% to $27.6 million in 2022, then skyrocketed by 130.26% to $63.6 million in 2023, then soared by 53.71% to $97.7 million in 2024, then dropped by 13.75% to $84.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $84.3 million in Q4 2025, $80.7 million in Q3 2025, and $107.5 million in Q2 2025.